Table 1.

Patient details and movement-related modulated in beta and gamma bands.

DOI: http://dx.doi.org/10.7554/eLife.19089.005

Patient ID	Age (yrs)	Gender	PD duration (yrs)	Main symptoms	Daily dose (mg)	UPDRS part III (Pre-op)		Movement related power change (%) and electrode localisation												Stimulation effect
								Left STN						Right STN
						OFF	ON	Bipoloar channel	Beta ERD	Gamma ERS	Localisation	Most %beta	Stim setting	Bipoloar channel	Beta ERD	Gamma ERS	Localisation	Most % beta	Stim setting
1 QS	49	M	13	Stiffness, bradykinesia, bilateral tremor, freezing	Levodopa 800 Apomorphine (6.5 mg/hour) Rotigotine 8	38	13	L1L2	−4.52 (*)	17.99 (*)	L1,L2 border MED	L1	Case: + L1: -	R1R2	1.15	33.2 (*)	R0:inside/border/MED; R1: border/MED	R0	Case: + R1: -	UPDRS OFF Med, Stim ON/OFF: 13/38
2 Ox	69	M	11	Rigidity, bradykinesia, freezing	Ropinirole 8 Pramipexole 0.75 Levodopa 900	38	18		--	--	Electrode was not in target and therefore not recorded			R0R1	−4.79	0.92	R0,R1 inside only	R1	None	Stimulation was discontinued shortly after surgery due to unsatisfactory clinical effect
3 King	65	F	17	Rigidity, tremor	Amantadine 400 Levodopa 600	55	49	L0L1	−5.12 (*)	7.44 (*)	All inside	L1	Case: + L0: -	R0R1	−29.03 (*)	3.29 (*)	All inside	R1	Case: + R1: -	Not evaluated
4 QS	56	M	10	Bradykinesia, rigidity, tremor limping gait	Levodopa 1000 Rasagiline 1 Citalopram 20	40	12	L1L2	−2.48 (*)	37.73 (*)	L1,L2,L3 inside; L2 dorsolat	L2	Case: + L1: -	R0R1	−18.92 (*)	2.98 (*)	R0 inside; R1 border/dorsolat	R1	Case: + R0, R1 (alternating): -	UPDRS OFF Med, Stim ON/OFF: 29/40
5 QS	60	F	11	Tremor@Left; poor coordination, bended gait	Levodopa 600 Pramipexole 0.75	53	16	L1L2	−4.94 (*)	6.68 (*)	All inside; L1 dorsolat	L1	Case: + L1: -	R2R3	−0.049	2.14	R1 inside; R2 border	R2	Case: + R1: -	Not evaluated
6 Kings	65	M	5	Rigidity, bradykinesia, motor fluctuation, tremor	Levodopa 400 Entacapone 800 Rotigotine 8	41	29	L1L2	3.33	1.81	All inside	None	Case + L2: -	R1R2	−7.37 (*)	0.66	All inside	R2	Case + R1: -	Not evaluated
7 QS	56	M	10	tremor@all four limbs	Levodopa 600 Rotigotine 8 Selegiline 10	52	19	L0L1	−10.68 (*)	8.42 (*)	L2, L3 in superior STN	L0	Case: + L1: -	R0R1	−22.76 (*)	14.02 (*)	R0, R1 in STN, R2 lateral border of superior STN	R1	Case + R1: -	Relocation after recording due to side effects on speech
8 Kings	73	M	14	Bradykinesia, tremor	Rotigotine 16 Selegeline 10 Levodopa 700	35	15	L0L1	0.157	−0.186	All inside	None	Case: + L1: -	R1R2	−4.93 (*)	5.57 (*)	All inside	R1	Case: + R1: -	Not evaluated
9 Ox	63	F	14	Rigidity, bradykinesia	Ropinirole 23 Levodopa 150	35	24		3.197	−1.14	None inside	None	None		−2.59	7.20	None inside	None	None	Post-op imaging show mis-location, and electrodes were relocated to GPi
10 QS	66	F	16	Shuffle, poor balance, NO tremor	Levodopa 600 Amantadine 200 Ropinirole 24 Rasagiline 1	32	13	L0L2(L1 no signal)	4.33	2.95	L0,L1 inside	L0	Case: + L1: -	R0R1 (bipolar reduced modulation)	−1.37	7.41 (*)	R1,R2 inside	R1	Case: + R1: -	UPDRS OFF Med, Stim ON/OFF: 26/32
11 QS	52	M	7	Freezing, falls, postural instability, tremor@right side	Levodopa 1300 Citalopram 20 Trihexyphenidyl 6	58	13	L1L2 (bipolar reduced modulation)	38.77	13.22		L2	Case: + L1: -	R1R2 (bipolar reduced modulation)	−1.05	1.11		R1	Case: + R1: -	Relocation after recording
Mean	61.3		11.3			43.4	20.1

(*) Indicate significant movement-related modulation in the power of the activity of the specific frequency band; Ox, Kings, QS indicate the three neurosurgical centres where the data were recorded: Ox = John Radcliffe Hospital, University of Oxford; Kings = Department of Neurosurgery, Kings College Hospital, Kings College London; QS = Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology.